Terms ending in 2038
Every in-force patent on Purdue Pharma L.P.'s record whose computed term ends in 2038, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 12,297,199 | Morphinan Derivatives and Use Thereof In force · Medium confidence | Purdue Pharma L.P. | In force | Medium confidence | |
| US 11,413,276 | Compounds for Treating TNBC In force · High confidence | Knoa Pharma LLC | In force | High confidence | |
| US 11,786,509 | Compounds for Treating TNBC In force · High confidence | Knoa Pharma LLC | In force | High confidence | |
| US 11,918,558 | Tinostamustine for Use in the Treatment of T-Cell Prolymphocytic Leukaemia In force · High confidence | Knoa Pharma LLC | In force | High confidence | |
| US 12,303,492 | Compounds for Treating TNBC In force · High confidence | Knoa Pharma LLC | In force | High confidence | |
| US 12,370,178 | Tinostamustine for Use in the Treatment of T-Cell Prolymphocytic Leukaemia In force · High confidence | Knoa Pharma LLC | In force | High confidence | |
| US 12,201,629 | Method of Treatment and Dosage Forms Thereof In force · High confidence | Purdue Pharma L.P. | In force | High confidence | |
| US 11,318,117 | Tinostamustine for Use in the Treatment of T-Cell Prolymphocytic Leukaemia In force · High confidence | Mundipharma Edo GmbH | In force | High confidence | |
| US 11,896,583 | Tinostamustine for Use in Treating Ovarian Cancer In force · High confidence | Knoa Pharma LLC | In force | High confidence | |
| US 11,911,510 | Pharmaceutical Dosage Forms In force · High confidence | Purdue Pharma L.P. and Purdue Pharmaceuticals L.P. | In force | High confidence | |
| 3 more term ends in 2038 · Pro | |||||
10 of 13 patents shown. Soonest term end first, then patent number.
Pro members see all 13.
5 of these are in force and held by Purdue Pharma L.P..
Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.